drugset
drugset / Trial / NCT01808612

A Study of Fluoxetine in Major Depressive Disorder (MDD) Short-Term Dosing

NCT01808612 ↗

Phase 3 Completed 513 enrolled Eli Lilly and Company
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to evaluate the short-term efficacy and safety of Fluoxetine in Japanese adult participants with Major Depressive Disorder (MDD).

Timeline

Start
2013-03
Primary completion
2014-07
Completion
2014-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Fluoxetine Small molecule 20 mg Oral
Subject Fluoxetine Small molecule 40 mg Oral

Indications

major depressive disorder